HUE029921T2 - Influenzát gátló készítmények és eljárások - Google Patents

Influenzát gátló készítmények és eljárások Download PDF

Info

Publication number
HUE029921T2
HUE029921T2 HUE08779763A HUE08779763A HUE029921T2 HU E029921 T2 HUE029921 T2 HU E029921T2 HU E08779763 A HUE08779763 A HU E08779763A HU E08779763 A HUE08779763 A HU E08779763A HU E029921 T2 HUE029921 T2 HU E029921T2
Authority
HU
Hungary
Prior art keywords
leu
influenza
glu
asn
gly
Prior art date
Application number
HUE08779763A
Other languages
English (en)
Inventor
Robert F Garry
Russell B Wilson
Original Assignee
The Administrators Of The Tulane Educational Fund
Autoimmune Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund, Autoimmune Tech Llc filed Critical The Administrators Of The Tulane Educational Fund
Publication of HUE029921T2 publication Critical patent/HUE029921T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/11Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/00033Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (7)

  1. S*ahaäatot igénypontok
    1. Izolált pepiid, amely aroinosav-szckvencíáját tekintve SEQ ÎD MO: .3 szeriöÉ: anmiosav* szekvenciából áll, infi«enzavlnis4ertözés kezelésére szolgáló eljárásban tertéoö alkalmazásra.
  2. 2. Az 1. igénypont szerinti Izolált pepiid az ott meghatározoti alkalmazásra, amely taríáloiág lipid szubsztittiesssf.
  3. 3. Gyógyászati készítmény, amely tartalmaz 1, vagy 3, igénypont szerinti, az ott méghittározötí alkalmazásra szolgáló pepiidet győgyászatilag elfogadható hordozóban. 4. A 3, igénypont szerinti gyógyászati készittnény az ött meghatározott alkalmazásra^ ahol: a győgyászatilag elfogadható hordozó pufforeit: sétáidat, 5. A 3. igénypont szerinti gyógyászati készítmény az ott tnegbmdrozott alkalmazásra, ahol a készítmény beMlegszheíópor fornmjában van.
  4. 6. Az I, igénypont szerinfl izolált psptid az ott ttisgftaíáfozott alkalmazásra, ahol az jnttanzayírus« fertőzés Hl. H3 vagy H5 altfp«sp InittéPza Aféttdkés.
  5. 7. Az 1, igénypont szerinti izolált pepiid az-ott ntegÍMtározött áikálmazásra, aittd az influettzavírus-fertözés influenza 8 fertőzés,
  6. 8. Izolált pepiid, amely atsinösav^zékveneiáját lekÄd 'szerinti aminosav-székven- etáfeói all, iníluettzávh'os-lertttzés kezelésére szolgáló eijáFás^:^ttteü^#.|yógys%er eidáilftásábaa történő alkalmazásra. 9. A 8, igényporu szerinti Izolált pepiid: azt olt megítátátözótt ailálrnazásra, amely tartalmaz lipid szubszi látenst, lő. Gyógyászati készítmény. amely tartalmaz 8. vágy 9. igénypont szerinti, az ott meghatározott alkalmazásra szolgáló pepiidet gyógyászat il ag elfogadható hofdózőfeap, i l, A 10. igénypont széiinfi gyógyászati k&zftisijftf -m.M :.i»|b®èfoi:oîli álkalmézásra, ahoi a gyógyászsiiiag elfogadható hordozó pufsémii sóoldat.
  7. 12, A lő, igénypont szénníi gyógyászati készítmény az ott meghatározót! alkalmazásra, ahol a. készítmény belélegezheíő por formájában van, 13, A 8, igénypont szerinti izolált pepiid az ott ; meghatározottí alkalmazásra, áltól az iniloenzaylrns·-íéftőzés 111, U3 vagy 115 altípusai influenza Λ fertőzés. 14, A 8. Igénypont szerinti izolált pepiid az ott tíiíSgíiítiaf^í^Ott íitkítlííí^Kásí'á, ahol m iáÖóénZáVífMS-fertőzés influenza B fertőzés.
HUE08779763A 2007-06-25 2008-06-25 Influenzát gátló készítmények és eljárások HUE029921T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93712007P 2007-06-25 2007-06-25

Publications (1)

Publication Number Publication Date
HUE029921T2 true HUE029921T2 (hu) 2017-04-28

Family

ID=40185954

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08779763A HUE029921T2 (hu) 2007-06-25 2008-06-25 Influenzát gátló készítmények és eljárások

Country Status (18)

Country Link
US (2) US8604165B2 (hu)
EP (1) EP2170365B1 (hu)
JP (2) JP5450402B2 (hu)
KR (4) KR101660363B1 (hu)
CN (2) CN105237629B (hu)
BR (1) BRPI0813922A2 (hu)
CA (1) CA2691358C (hu)
DK (1) DK2170365T3 (hu)
EA (1) EA017957B1 (hu)
ES (1) ES2581381T3 (hu)
HK (2) HK1142804A1 (hu)
HU (1) HUE029921T2 (hu)
IL (2) IL202450A (hu)
MX (2) MX2009013635A (hu)
PL (1) PL2170365T3 (hu)
PT (1) PT2170365T (hu)
WO (1) WO2009002516A1 (hu)
ZA (1) ZA200909130B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
EP3492101A3 (en) * 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Agents for influenza neutralization
US9649375B2 (en) * 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3548056A4 (en) * 2016-12-02 2020-08-12 Emory University PEPTIDES AND USES FOR VIRUS INFECTION MANAGEMENT
IL298035A (en) 2020-05-08 2023-01-01 Academia Sinica Chimeric influenza vaccines
CN113801206A (zh) * 2020-06-15 2021-12-17 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
WO2021253172A1 (zh) * 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) * 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
AU732916C (en) * 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CA2398787A1 (en) 2000-02-10 2001-08-16 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
WO2005016238A2 (en) 2003-05-08 2005-02-24 Duke University Severe acute respiratory syndrome
TW200510450A (en) 2003-07-21 2005-03-16 Nat Inst Health Soluble fragments of the SARS-CoV spike glycoprotein
PT2261376E (pt) * 2003-11-04 2013-09-23 Univ Tulane Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DE102005060920A1 (de) * 2005-12-18 2007-06-21 Charité - Universitätsmedizin Berlin Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung
AU2007300663A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
EA201070053A1 (ru) 2010-08-30
IL238404A0 (en) 2015-06-30
JP5764621B2 (ja) 2015-08-19
MX363240B (es) 2019-03-15
ZA200909130B (en) 2010-09-29
AU2008269081A1 (en) 2008-12-31
US9353157B2 (en) 2016-05-31
PT2170365T (pt) 2016-07-12
EP2170365A1 (en) 2010-04-07
DK2170365T3 (en) 2016-09-05
CN105237629A (zh) 2016-01-13
KR20160113331A (ko) 2016-09-28
US20100152109A1 (en) 2010-06-17
CA2691358C (en) 2017-08-22
CN101848719A (zh) 2010-09-29
MX2009013635A (es) 2010-05-19
KR20100056442A (ko) 2010-05-27
KR101660363B1 (ko) 2016-09-28
US20140194347A1 (en) 2014-07-10
KR101719135B1 (ko) 2017-03-23
JP5450402B2 (ja) 2014-03-26
BRPI0813922A2 (pt) 2017-05-09
ES2581381T3 (es) 2016-09-05
IL202450A0 (en) 2011-08-01
JP2010531362A (ja) 2010-09-24
PL2170365T3 (pl) 2017-03-31
WO2009002516A1 (en) 2008-12-31
EP2170365B1 (en) 2016-05-25
EP2170365A4 (en) 2012-05-02
KR20180021930A (ko) 2018-03-05
IL238404A (en) 2017-03-30
IL202450A (en) 2015-05-31
US8604165B2 (en) 2013-12-10
HK1215037A1 (zh) 2016-08-12
HK1142804A1 (zh) 2010-12-17
CN105237629B (zh) 2019-06-18
CA2691358A1 (en) 2008-12-31
EA017957B1 (ru) 2013-04-30
KR20150117303A (ko) 2015-10-19
CN101848719B (zh) 2015-09-23
JP2013241432A (ja) 2013-12-05

Similar Documents

Publication Publication Date Title
US9353157B2 (en) Influenza inhibiting compositions and methods
RU2236865C2 (ru) Гибридные полипептиды с улучшенными фармакокинетическими свойствами
AU2012362121B2 (en) Stabilized antiviral fusion helices
US8222204B2 (en) Influenza inhibiting compositions and methods
CN104151403B (zh) 一类多肽或其衍生物、及其在流感病毒感染中的应用
US20130190228A1 (en) Novel antiviral peptides against influenza virus
AU2008269081B2 (en) Influenza inhibiting compositions and methods
CN108822190B (zh) 多肽及其药物组合物和用途
AU2017350304A1 (en) Influenza virus neutralizing compounds
JP2018070571A (ja) 免疫誘導剤
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof